NEUROCRINE BIOSCIENCES INC
NBIXAPI behind this page
NBIX Q1 2026 request
Playground key active
/api/financials?ticker=NBIX&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 814.5 | 572.6 | +42.2% |
Show Product Lines breakouts |
|||
| Collaboration revenues | 3.5 | 8.9 | -60.7% |
| Product | 811 | 563.7 | +43.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 814.5 | 572.6 | +42.2% |
| Reportable Segment · CRENESSITY net product sales | 153.3 | 14.5 | +957.2% |
| Reportable Segment · INGREZZA net product sales | 656.9 | 545.2 | +20.5% |
| Reportable Segment · Other Income | 4.3 | 12.9 | -66.7% |
| Cost of Revenue | 13.8 | 9.2 | +50.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 13.8 | 9.2 | +50.0% |
| Research And Development Expense Excluding Acquired In Process Cost | 296.2 | 263.2 | +12.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | 296.2 | 263.2 | +12.5% |
| Reportable Segment · External research and development | 148 | 107.9 | +37.2% |
| Reportable Segment · Milestones | 22.6 | 45.4 | -50.2% |
| Reportable Segment · Other research and development | 41.1 | 34.9 | +17.8% |
| Reportable Segment · Payroll and benefits | 84.5 | 75 | +12.7% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 21.2 | 0.1 | +21100.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 21.2 | 0.1 | +21100.0% |
| Selling, General & Administrative | 318.5 | 276.5 | +15.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 318.5 | 276.5 | +15.2% |
| Gain Loss On Sale Of Business | -28.6 | — | — |
| Total Costs & Expenses | 621.1 | 549 | +13.1% |
| Operating Income | 193.4 | 23.6 | +719.5% |
| Equity Securities Fv Ni Unrealized Gain Loss | 25.3 | -30.6 | +182.7% |
Show Business Segments breakouts |
|||
| Reportable Segment | 25.3 | -30.6 | +182.7% |
| Investment Income And Other Net | 28.1 | 21.7 | +29.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | 28.1 | 21.7 | +29.5% |
| Non-Operating Income (Expense) | 53.4 | -8.9 | +700.0% |
| Income Before Taxes | 246.8 | 14.7 | +1578.9% |
| Income Tax Expense (Benefit) | 48.9 | 6.8 | +619.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 48.9 | 6.8 | +619.1% |
| Net Income | 197.9 | 7.9 | +2405.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 197.9 | 7.9 | +2405.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 197.9 | 7.9 | +2405.1% |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -12.7 | 1.7 | -847.1% |
| Comprehensive Income | 185.2 | 11.1 | +1568.5% |
| EPS (Basic) | 1.97 | 0.08 | +2362.5% |
| EPS (Diluted) | 1.91 | 0.08 | +2287.5% |
| Wtd Avg Shares (Basic) | 100.5 | 99.7 | +0.8% |
| Wtd Avg Shares (Diluted) | 103.4 | 102.5 | +0.9% |
| Research & Development (Q) | — | — | — |
Show Counterparty Name breakouts |
|||
| Nxera · Collaborative Arrangement | 22.5 | — | — |
| Net Income Loss Available To Common Stockholders Basic | 197.9 | 7.9 | +2405.1% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 266.5 | 194.1 | +37.3% |
| Available For Sale Securities Debt Securities Current | 1,049.7 | 749.4 | +40.1% |
| Accounts Receivable | 768.1 | 516 | +48.9% |
| Inventory | 64.5 | — | — |
| Prepaid Expense Current | 224.8 | — | — |
| Other Assets Current | 62.5 | 119.3 | -47.6% |
| Total Current Assets | 2,436.1 | 1,637.9 | +48.7% |
| Non-Current Assets | |||
| Deferred Tax Assets | 381.4 | 499.4 | -23.6% |
| Available For Sale Securities Debt Securities Noncurrent | 1,331 | 815.3 | +63.3% |
| Operating Lease Right-of-Use Assets | 447.1 | 502.2 | -11.0% |
| Equity Securities Fv Ni Current And Noncurrent | 146.1 | 94.2 | +55.1% |
| Property, Plant & Equipment | 90.9 | 87 | +4.5% |
| Other Non-Current Assets | 73.6 | 15.3 | +381.0% |
| Total Assets | 4,906.2 | 3,687.7 | +33.0% |
| Current Liabilities | |||
| Accounts Payable And Accrued Liabilities Current | 773 | — | — |
| Other Liabilities Current | 58.7 | 47.7 | +23.1% |
| Total Current Liabilities | 831.7 | 522.9 | +59.1% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 406.2 | — | — |
| Other Non-Current Liabilities | 260.9 | — | — |
| Total Liabilities | 1,498.8 | 1,152 | +30.1% |
| Accrued Income Taxes Noncurrent | 241.3 | — | — |
| Stockholders' Equity | |||
| Common Stock | 0.1 | 0.1 | 0.0% |
| Additional Paid In Capital Common Stock | 2,817.3 | 2,531.9 | +11.3% |
| Accumulated Other Comprehensive Income | 0.4 | 9 | -95.6% |
| Retained Earnings | 589.6 | -5.3 | +11224.5% |
| Total Stockholders' Equity | 3,407.4 | 2,535.7 | +34.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 0.4 | 9 | -95.6% |
| Additional Paid In Capital | 2,817.3 | 2,531.9 | +11.3% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 589.6 | -5.3 | +11224.5% |
| Total Liabilities & Equity | 4,906.2 | 3,687.7 | +33.0% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 57.2 | 52.8 | +8.3% |
| Depreciation | 7.2 | 6.6 | +9.1% |
| Accretion Amortization Of Discounts And Premiums Investments | -1.3 | -4.6 | +71.7% |
| Amortization Of Intangible Assets | 0.1 | 1 | -90.0% |
| Deferred Income Taxes And Tax Credits | -61.1 | -13.7 | -346.0% |
| Operating Lease Right Of Use Asset Amortization Expense | 2.7 | 7.2 | -62.5% |
| Disposal Group Not Discontinued Operation Gain Loss On Disposal | -28.6 | — | — |
Show Disposal Group Classification breakouts |
|||
| Disposal Group Disposed Of By Sale Not Discontinued Operations · Neurocrine Group Limited | -28.6 | — | — |
| Change in Accounts Receivable | -81.4 | -36.9 | -120.6% |
| Change in Inventory | 4.3 | -1.7 | +352.9% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -14.3 | -3 | -376.7% |
| Increase Decrease In Income Taxes | 119.8 | 15.4 | +677.9% |
| Increase Decrease In Other Operating Capital Net | -31.4 | 2.5 | -1356.0% |
| Net Cash from Operations | 145.8 | 64.8 | +125.0% |
| Investing Activities | |||
| Purchases of Investments | -819.5 | -273.2 | -200.0% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 259.2 | 298.1 | -13.0% |
| Proceeds From Divestiture Of Businesses | 63.2 | — | — |
| Capital Expenditures | -9.1 | -10.7 | +15.0% |
| Net Cash from Investing | -506.2 | 14.2 | -3664.8% |
| Financing Activities | |||
| Proceeds From Issuance Of Common Stock | 23.6 | 32.1 | -26.5% |
| Tax Withholding for Share Compensation | -55.7 | — | — |
| Share Repurchases | -54 | -150 | +64.0% |
| Net Cash from Financing | -86.1 | -117.9 | +27.0% |
| Supplemental | |||
| Unpaid Capital Expenditures | 1.4 | 2.7 | -48.1% |
| Income Taxes Paid | 0.3 | 0.6 | -50.0% |
| Other Cash Flow | |||
| Net Change in Cash | -446.5 | -38.9 | -1047.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 274.5 | 202.1 | +35.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.